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pcDNA3-HERG by site-directed mutagenesis, expressed by transient transfection of 
human embryonic kidney ceils, and characterized electrophysiologically. 
Results: 8 of the 93 cases of SIDS possessed 4 novel nonsynonymous ingle nucteotide 
polymorphisms (SNPs, amino acid variants). However, 3 of the variants were identified in 
ethnic-matched controls. A putative SIDS-causing HERG mutation was found in exon 4 
from a 6-month-old Caucasian male. This N-terminal mutation was not present in 200 
alleles from Caucasian controls. Functionally, this mutation results in significantly 
decreased levels of whole cell current compared to wild type. 
Conclusions: Approximately 1% of this prospective, population-based cohort of SIDS 
cases had an identifiable HERG channel defect. This study implicates cardiac eotassium 
channels in SIDS for the first time. In addition, the study illustrates the importance of eth- 
nic-matched controls to avoid the erroneous assignment of novel nonsynonymous SNPs 
as putative BIDS-causing mutations. 
10:45 a.m. 
857-2 Effect of Phenylephrine Provocation on Dispersion of 
Repolarization in Congenital Long QT Syndrome 
Anant Khositseth, Jan Nemec, Joseph Hejiik, Win K. Shen, Michael J. Ackerman, Mayo 
Clinic, Rochester, Minnesota. 
Background: Syncope or sudden cardiac arrest is associated with sympathetic stimula- 
tion in LQT1. LQT2 and LQT3 patients are more susceptible to arrhythmias at lower 
heart rates. Spatial dispersion of repolarization is estimated by QT dispersion (QTd = 
QTmax - QTmin) whereas transmurel dispersion of repolarization (TDR) is estimated by 
the interval from T peak to T end (Tp-e). This study compares the effect of phenylephrine 
on QTd and TDR in genotyped long QT syndrome (LQTS) to control (C). 
Methods: 17 patients (12 F, 26,9 + 11.6 years) with LQT1, 15 patients (8 F, 26,7 + 12.9 
years) with LOT2/3, and 18 age- and gender- matched normal controls (10 F, 26.3 + 12.3 
years) were given a phenylephrine bolus intravenously at 2 mcg/kg. At baseline and at 
peak phenylephrine ffect, BP, QT, RR, Bazett's QT c, precordial QTd, and Tp-e intervals 
were determined blinded to the patient's clinical and genotype status. 
Results: Baseline QT intervals (482!-45 ms and 542+76 vs, 414±27) and OTc (476+26 
ms and 516+46 vs. 422+28) were significantly longer in LQT1 and LQT2/3 compared to 
control (p < 0.0001). Baseline QTd and Tp-e in LQT2/3 were greater than both LQT1 and 
control: QTd = 84+29 ms (LQT2/3), 53+25 (LQT1), 44+15 (C), p < 0.0001 and Tp-e = 
121:tr.28 ms (LQT2/3), 99+21 (LOT1), and 90+11 (C), p < 0.0003. Phenylephrine signifi- 
cantly increased blood pressure and slowed heart rate in all groups as expected. Phe- 
nylephrine exerted no significant effect on either QTd or Tp-e in all groups, Subgroup 
analysis of svmctomatic LOT1 (n=5) and symptomatic LQT2/3 (n=4) demonstrated a sig- 
nificant change in TDR following phenylephrine. In symptomatic LQT1, Tp-e decreased 
by 9 + 27 ms whereas Tp-e increased by 16 + 22 in symptomatic LOT2/3, p < 0.02). Phe- 
nylephrine tended to impact QTd differentially as well between symptomatic LOT1 and 
symptomatic LQT2/3 (-16 + 11 vs. 4 + 12). 
Conclusions: Phenylephrine-induced bredycardia decreased TDR in symptomatic 
LOT1 but increased TDR in symptomatic LOT2/3. The observed effects of phenylephrine 
are consistent with the protective effect of beta-bleeker therapy in LQT1 and the 
increased arrhythmogenicity noted during non-exertional states in LQT2/3. 
11:00 a.m, 
857-3 The Mechanism of Ventricular Arrhythmia on a Canine 
Isolated Blood-Perfused Brugada Syndrome Model 
Masaomi Kimura, Takao Kobayashi, Shingen Ohweda, Shingo Saseki, Tomonori 
Igarashi, Atsushi Iwasa, Shigeru Motomura, Ken Okumura, Hirosaki Universi~ Hirosaki, 
Japan. 
Background: Brugada syndrome is characterized by ST elevation in the right precordial 
leads and high incidence of ventricular arrhythmlas (VA). Phase 2 reentry was suggested 
as a mechanism for VA in the canine right ventricular (RV) preparation perfused with 
Tyrode solution. 
Methods: In an isolated canine RV preparation cross-circulated with arterial blood of the 
support dog (n=8), we simultaneously recorded a transmural ECG and 96 bipolar electro- 
grams using two rectangular plaque electrodes (35x30mm, each contained 48 elec- 
trodes) attached to the endocardial (ENDO) and epicardial aspects (EPI) of the 
preparation. Each preparation was paced at a cycle length of 800 msec. 
Results: Saddle-back and coved types of ST elevation were observed after administra- 
tion of a low (<51Jmol/L) and high doses (>8p.mol/L) of pilsicainide (a pure Na ÷ channel 
blocker), respectively, to the pertusion blood in addition to pinacidU (201Jmol/L). In 4 prep- 
arations, polymorphic ventricular tachycardia (V'I') developed after an extrasystole spon- 
taneously occurring from EPI at the middle of repelarization phase of the preceding beat. 
Activation map during the initial phase of v'r revealed unstable reentry between ENDO 
and EPI with migrating functional block (Figure). 
Conclusion: Thus, VT in this "Brugada syndrome model" was initiated by phase 2 reen- 
try in EPI and subsequent unstable reentry between ENDO and EPI. 
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857-4 Incidence of Patients at High Risk of Sudden Death 
Among Patients Referred for  the Suspicion of a 
Brugada-Syndrome: A Prospective Study in 35 
Consecutive Patients With Brugada-Like ECG Changes 
Constanze M. Echternach, Martin Borggrefe, Susanne Spahl, Ayse Bilbal, Michael 
Junker, Juergen Kuschyk, Tim S0selbeck, Karl K. Haase, Christian Wolpert, DepL of 
Cardiology, University Clinic Mannheim, University of Heidelberg, Mannheim, German~ 
Background: Since the Brugeda-like ECG changes are now familiar to a larger number of 
physicians, referral to specialized arrhythmia clinics for further diagnosis and risk stratifi- 
cation of patients presenting with an abnormal ECG in V1 to V3 is increasing. However, 
since the patients are very heterogenous with respect to family history, symptoms and 
age and sex, decision finding especially in asymptomatic patients remains still very diffi- 
cult, The aim of the study was to assess prospectively the incidence of patients with Bru- 
geda-like ECG changes who are at high risk according to the consensus in consecutive 
patients. Patients and methods: A total of 35 patients were referred to our arrhythmia unit 
for abnormal ECG in leads V1 to V3, 19/35 were of male sex. 12 patients had a history of 
syncope, 4 patients palpitations, 3 patients had aborted sudden death, two patients a car 
accident with non-observed loss of consciousness and 5 patients a positive family history 
of sudden death. All patients underwent ajmaline test, 6 patients additional flecainide 
test, 15 patients electrophysiological study. Results: Ajmaline test was positive in 12/35 
patients. In the 6 patients in whom ajmaUns test was positive, flecainide test was positive 
as well. 3/15 patients with a positive ajmaline test had inducible polymorphic VT or VF in 
the programmed stimulation. All of these patients had syncope and/or a positive family 
history. All three patients were implanted a csrdioverter-defibrillator. Device data storage 
did not reveal any v r  or VF events during a mean follow-up of 5 months. Conclusions: 1. 
The incidence of patients at high risk of sudden death among consecutive patients 
referred for Brugada-like changes in the surface ECG is 3/35 in the present observation. 
2. This justifies a full work up including invasive electrophysiological testing. 3. All 
patients who were inducible had either a positive family history or syncope. 
11:30 a.m. 
857-5 Clinical Noninvasive- lnvasive Evaluation and Five-Year 
Follow-Up in Patients With the Brugads Syndrome: A 
Prospective Excel-Access Database 
Franco NaccareHa, Giovannina Lepera, Stafano Maranga, Cardiologia Azienda USL 
Citt~ di Bologna, Bologna, Italy, Cardiology Herman Hospital Houston, Houston, Texas. 
PURPOSE. The Brugada Sindrome (BS) is characterized by clinical, ECG and pheno- 
type differences, the genetic characterization of which has not been completely per- 
formed. Furthermore, prognostic differences have been described in subjects suffering 
from a previous cardiac arrest (PCA), ECG abnormalities in rest condition (ECG R) or 
after flecainide infusion (ECG F), inducibility of major ventricular arrhythmias (IND.VA) at 
PES, syncopal episodes (SE) without evidence of VA. 
METHODS. To this purpose, we evaluated 64 subjects, belonging to nine different fami- 
lies suffering from BS, 7/9 with a proband member affected by PCA, 1/9 with VT, and the 
last one without IND VA. Patients with PCA were treated with an ICD, one patient with VT 
received Amiodarone (A). Patients with dubious ECG received Flecainide 1.5 (1-2) mg/ 
Kg infusion (FT). Results are reported in the following table, according to different 
aspects and symptoms of the disease, considering recurrences of CA, syncopal epi- 
sodes (SE) in a follow up (FUP) of 42 ± 12 months. 
CONCLUSIONS. 1) Different clinical evolutions over time can be observed in patients 
with the Brugada Syndrome and specific clinical features to begin with. 2) Mainly patients 
with CA and SE show the worst prognosis. 3) Normal ECG in asymptomatic patients with 
a negative FT are associated with a benign prognosis. 4) The role of FT and IND. VA at 
PES should be furtherly evaluated. 
OBS. RESULTS FUP CA 
PCA 7/9 7/7 (ICD) 2/7 2/7 
VT 1/9 1/1 (IND. VA) 1/1 0/1 
NO VTNF 1/9 0/1 (IND. VA) 1/t 0/1 
SE 9/64 3/9 (IND. VA) 3/3 2/3 
ECG R DUBIOUS 7/64 7/7 (+ FT) 
(IND VA) 3/7 (IND. VA) 3/3 1/3 
ECG R ATYPICAL 18/64 2/18 (+ FT) 
(non IND VA) 0/2 (IND. VA) 0/2 
11:45 a.m. 
857-6 Ajmaline Versus Procainamide Challenge Test in the 
Diagnosis of Sudden Unexplained Death or Brugada 
Syndrome 
Gumoanart Veerakul, Lertlak Chaothawee, Banharn Koanantakul, Koonlawee 
Nademanse, Cardiovascular Research Center, Bhumibol Adutyadej Hospital, RTAF, 
Bangkok, Thailand, Pacific Rim Electrophysiology Research Institute, Inglewood, 
California. 
Sudden Unexplained Death Syndrome (SUDS), is characterized by an abnormal ECG 
with ST-elevation in V1-V3 and sudden death, similar to that seen in the Brugeda syn- 
drome. But the ECG marker waxes and wanes and may be normal at the initial presenta- 
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tion. Sodium channel blockers and higher ECG lead positioning have been shown to 
unmask the ECG marker. But the sensitivity and specificity of each provocation alone 
and in combination is unknown. Thus, we studied 21 SUDS males (age 44 + 13 yrs), who 
had no heart disease with normal ECG and 8 matched normal males. Eleven of the 21 
SUDS patients (pts) had VF and the other 10 had SUDS like symptoms or syncope; 19 of 
the 21 pts had inducible VT. All underwent conventional ECG (V1-3 at the 4 th intercostal 
space [ICS]) and the higher ICS lead positioning (V1-3 at the 2 nd and 3 rd ICS) at base- 
line, during Ajmatine (Aj) 1 mg/kg and during procainamide (Proc) 10 mg/kg (each drug 
was given 24 hrs apart). Our results show that higher ICS lead positioning and Aj or Proc 
alone modestly increased the sensitivity of unmasking the abnormal ECG pattern, the 
best outcome is when combining the drug with higher lead positioning. None of the nor- 
mal control subjects had an abnormal ECG pattern with any of these provocative maneu- 
vers, alone or in combination. Conclusion: Sodium channel blockers, in combination with 
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higher lead (V1-V3) positioning, have 100% specificity and over 75% sensitivity for the 
diagnosis of SUDS or Brugada syndrome. And Aj is more sensitive than Proc (95% ver- 
sus 76%). 
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859 Catheter Ablation: Insights from 
Concomitant Imaging 
Tuesday, March 19, 2002, 10:30 a.m.-Noon 
Georgia World Congress Center, Room 367W 
10:30 a.m. 
859-1 Prospective Evaluation of Characteristic 
Echocardiographic Imaging Signature Associated With 
Successful Ablation of Inappropriate Sinus Tachycardia 
Jian-fano Ran. Francis E. Marchlinski, David J. Caltans, University of Pennsylvania, 
Philadelphia, Pennsylvania. 
Background: A characteristic intracardiac echocardiographic (IE) signature suggesting 
transmural/epicardial damage is associated with successful heart rate reduction during 
anatomically-guided ablation of inappropriate sinus tachycardia (IST). This study is to fur- 
ther evaluate if this may be used as an appropriate endpoint for procedural success. 
Methods: Detailed on-line videotape IE (9MHz, 9Fr) imaging monitoring was performed 
in 5 pts (all women, age 35-+13yrs) with IST. Radiofraquency (RF) ablation was anatomi- 
cally-based and targeted mainly the superolateral crista terminalis (CT) guided by IE. 
Lesions were created with 20-50w for up to 2 minutes using an 8-ram tip electrode. 
Echodensity changes reaching to the epicardium with the development of a complete lin- 
ear echo-free space (following expansion of wall swelling around the CT and superior 
vena cava [SVC]) and the ablation number (time) associated with heart rate reduction 
were carefully assessed during the procedure. Results: Successful heart rate reduction 
(from 112_+54 to 76~8 beats/rain) was achieved in all 5 pts and required 38_+12(range 28 
to 67) RF applications. A transient heart rate reduction started when an incomplete linear 
(segmental) echo-free space developed at the 22nd~14th lesion. With further IE guided 
lesion deployment, a complete linear echo-free space developed finally covering whole 
superolateral CT area. This indicated appropriate endpoint when sustained heart rate 
reduction was observed in all 5 pts (4/5 pts with the p wave in lead III changed from a 
positive to a fiat or negative direction). Craters and thrombus formation were observed 
within the lesions, No other procedural related complications, such as SVC-RA junction 
narrowing >50% or pericardiat effusion, were identified. No recurrence for symptoms 
from ablated IST was observed over a foUowup period of 2 to 9 months. Conclusion: A 
characteristic IE imaging signature of the development of a complete echo-free space at 
CT may provide an appropriate endpoint for procedural success of IST ablation. 
10:45 a.rn. 
859-2 Reso lu t ion  of  Increased Pulmonary Vein Flow Velocity 
Following Radio Frequency Ablation for Atrial 
Fibrillation: A Doppler Color Flow Imaging Follow-Up 
Jian-fano Ran, David J. Callans, Francis E. Marchlinski, University of Pennsylvania, 
Philadelphia, Pennsylvania. 
An increased flow velocity reflects ostial/lumen narrowing in the ablated pulmonary vein 
(PV) following catheter ablation for atrial fibrillation (AF). The present study was to char- 
acterize the magnitude and time course of flow velocity changes using an AcuNav ultra- 
sound catheter (UC) during repeat procedures targeting the same PV and evaluate the 
flow velocity response to the repeat ablation. Methods: Out of 174 pts with AF undergo- 
ing LA ablation (78 had UC PV flow study) involving at least one PV ostium, 18 (16men; 
age 53_+9yrs) had repeat ablation (upto 52°C,40W,90sec) for recurrent AF (9.5±7months 
followup), The peak velocity (V, cm/s) of PV ostial flow was measured Pre- and Post-abla- 
tion. Results: V was assessed in 28/31 PVs (initial) previously targeted with followup 
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measurement at intervals of 3 days (n=2 PVs), I to 3 months (M) (n=6), 4 to 12M (n=15), 
and 13 to 30M (n=5)(Table). The V measured >100cm/s Pre-rapeat ablation only in 2 pts: 
One was 110cm/s at an interval of 3 days (vs. 129cm/s post-initial ablation) and the other 
remained at 137cm/s after 2.9M followup. There was no significant difference for 
increased V following repeat ablation at previously targeted PV (n=17 PVs; 64_+8 Pro- vs. 
118-+28 cm/s Post-) as compared to those of previously non-targetad PVs (n=12; 62+12 
vs. 120-+36). Conclusion: Increased PV ostial flow acutely after lesion deployment 
appears to resolve within 3 months. V of PV flow after repeat ablation of previously tar- 
geted PV is comparable to V of non-targeted or PV with initial ablation. 
Initial Pre- Post- Followup 3 days 1-3M 4-12M 13-30M 
52-+10cm/s 10t+_24 86_+35 71_+33 56-+10 52-+6 
(range 26-63) (73-137) (61-110) (47-137) (37-71) (46-61) 
11:00 a.m. 
859-3 Acute Changes in Pulmonary Vein Flow Do Not Predict  
Chronic Pulmonary Vein Stenosis Following Atrial 
Fibrillation Ablation 
Christooher R. Cole. Nassir E Marrouche, Thomas J. Dresing, Alejandro Peraz-Lugones, 
Krzysztof Balaben, Eduardo Saad, Patrick Tchou, Andrea Natale, Cleveland Clinic 
Foundation, Cleveland, Ohio. 
Background: Electrical isotation of the pulmonary veins with radiofraquency ablation is 
used for the treatment of atrial fibrillation. A serious potential complication of this proce- 
dure is pulmonary vein stenosis. Measurement of the pulmonary vein flow with intrecar- 
diec echo pre- and post-ablation has been advocated as a method of predicting which 
patients will go on to develop chronic pulmonary vein stenosis. However, this hypothesis 
has never been tested. 
Methods; We measured pre- and post-ablation diastolic pulmonary vein flow in each of 
the 4 pulmonary veins using a phased-array intracardiac echo catheter (Accuson) in 47 
patients (age 51±11) undergoing afib ablation. The ostium of each of the pulmonary 
veins was defined using angiography, electrical mapping and the intracardiac echo cath- 
eter. Electrical isolation all 4 pulmonary veins was achieved using a 4-ram cooled-tip 
radiofrequency ablation catheter (Cardiac Pathways). Change in pulmonary vein flow, 
when present, was examined as both an absolute value and as a percentage of the 
baseline flow. All patients underwent spiral computed tomography (CT) scans of the pul- 
monary veins 2 months after the procedure. Stenosis was defined as mild (70%). 
Regression analysis was used to determine the correlation coefficient (r) between pulmo- 
nary vein flow change and pulmonary vein stenosis. 
Results: The average pre-ablation flows for the left superior, left inferior, right superior 
and right inferior veins were 0.56, 0.54, 0.47 and 0.45 m/s respectively. These increased 
to 0.74, 0.67, 0.58 and 0.89 m/s post-ablation. The absolute increase in flow ranged from 
0 to 0.8 m/s. The maximum flow change as a percentage was 200%. Of note, chronic 
stenosis did not occur in either of the patients who had high acute flow changes. Out of 
188 pulmonary veins ablated, the CT scans revealed 2 (1%) with significant stenosis, 5 
(3%) with moderate stenosis and 39 (20%) with mild stenosis of the pulmonary veins. 
The r-value between flow and stenosis was only 0.06 (p=ns). 
Conclusions: Acute changes in pulmonary vein flow assessed by intracardiac echo do 
not appear to be a strong predictor of chronic pulmonary vein stenosis. 
11:15 a.m. 
859-4 Comprehensive and Detailed Analysis of Pulmonary 
Veins, Left Atrial Appendage, and Their Interrelations 
With Gadolinium Enhanced Magnetic Resonance 
Angiogrephy and 3-D Navigation View Analysis 
Lars M. Lickfett, Ritsushi Kato, Henry Halperin, Stephen Sotomon, Tim Dickfeld, Khurram 
Nasir, Glenn Mainingar, Richard Wu, Charles Leng, Georg Juang, Kevin Donahua, 
Gordon Tomaselli, Ronald Berger, Hugh Calkins, Johns Hopkins Hospital, Baltimore, 
Maryland. 
Background: Atrial fibrillation (AF) can be cured by electrical isolation of the pulmonary 
veins (PV). Elimination of PV potentials has been proposed as the optimal endpoint for 
ablation. However, it is often difficult to distinguish PV potentials from far field potentials 
created by the left atrial appendage (LAA) and other structures. The purpose of this study 
was to use magnetic resonance angiography (MRA) to explore the anatomical relation- 
ships between the PV and LAA in patients (pt) referred for focal AF ablation. 
Methods: Breath hold gadolinium enhanced MRA, using a 1.5 T cardiac MR imager 
(GE), was performed in 15 consecutive patients (pt) who underwent catheter ablation of 
focal AF at this institution (4 female,51+13 yrs). 3D reconstructed images of the left 
atrium (LA) and PV were obtained. 3D navigation views were used to determine the dis- 
tance between the LAA and the left PVs. 
Results: In these pt with AF the LA volume was 88.8+~4.6 cc (range 49.2-127.3). The 
left LAA area was 6.2 cm 2 (range 2.2-9.3). The LAA was positioned in close proximity to 
the left superior PV with a distance of 4.8+0.9 mm (range 3.5-6.3) between the ostia of 
these two structures. The distance from the LAA to the left inferior PV was 7.3_+3.5 mm 
(range 3.1-12.9). The PV anatomy was highly variable with one common ostium of the 
left PV, 2 pt demonstrating a shared mouth with a very short neck and two pt demonstrat- 
ing a right middle PV. The overall diameter of the PV ostia was 18.2:~..7 ram. The pattern 
of vein branching was significantly different (p<0.05) between the left and right PVs with 
the 1st branching occurred 23.4_+5.4 mm (range 16.9-33.8) from us in the LSPV, 18_+4.2 
mm (range 13.7-27.1) in the LIPV, 12.7±4.1 mm (range 6.8-23.3) in the RSPV and 
11.2+4 mm (range 5-18.3) in the RIPV. 
Conclusions: The results of this study reveal a close anatomic relationship between the 
left superior pulmonary vein and the left atrial appendage. This may account for the 
